


## 20S Proteasome activator 1

<b>Cat. No.:</b>	HY-150602		
<b>CAS No.:</b>	2761578-18-9		
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>19</sub> ClF <sub>2</sub> N <sub>2</sub> OS		
<b>Molecular Weight:</b>	492.97		
<b>Target:</b>	Proteasome		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (202.85 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.0285 mL	10.1426 mL	20.2852 mL
		5 mM	0.4057 mL	2.0285 mL	4.0570 mL
10 mM		0.2029 mL	1.0143 mL	2.0285 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.07 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	20S Proteasome activator 1 is a potent 20S proteasome activator with EC <sub>200</sub> values of 0.3 μM, 0.7 μM and 1.8 μM for trypsin-like site, chymotrypsin-like site and caspase-like site. 20S Proteasome activator 1 translates well in a cellular system, preventing the accumulation of the pathogenic A53T mutant of α-synuclein. 20S Proteasome activator 1 can be used for researching neurodegenerative diseases <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 0.3 μM (trypsin-like site), 0.7 μM (chymotrypsin-like site), 1.8 μM (caspase-like site) <sup>[1]</sup>
<b>In Vitro</b>	20S Proteasome activator 1 (compound 19) (2.5-15 μM; 45 min) degrades 73% α-synuclein at 10 μM, and over 80% at 15 μM <sup>[1]</sup> . 20S Proteasome activator 1 (5-15 μM; 24 h) reduces 25% A53T mutant, and dose-dependently reduces enhancement of α-synuclein in Hek-293T cells (transiently transfected with an A53T mutant α-synuclein plasmid) at 5 μM; decreases 67% A53T α-synuclein at 15 μM <sup>[1]</sup> .

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Staerz SD, et al. Design, Synthesis, and Biological Evaluation of Potent 20S Proteasome Activators for the Potential Treatment of  $\alpha$ -Synucleinopathies. J Med Chem. 2022 May 12;65(9):6631-6642.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA